Labcorp holds diagnostic data from more than 75 million patients — a longitudinal archive accumulated over decades of testing that no competitor can replicate by building a better lab or hiring more technicians. That data asset sits inside what most people think of as a blood test company, but it increasingly functions as the foundation for drug development partnerships, clinical trial operations, and specialty diagnostics that carry margins the routine testing business cannot generate. The Burlington, North Carolina company generated $13.01 billion in FY2024 revenue and $746 million in net income through two primary segments. Diagnostics Laboratories handles routine and specialty testing for patients, physicians, and health systems across the United States. The Biopharma Laboratory Services segment — the former Covance business, acquired in 2015 — runs clinical trials and provides laboratory services to pharmaceutical and biotechnology companies developing new drugs. CEO Adam H. Schechter leads a workforce of 70,000 people across a network that processed approximately 2.5 billion test results annually. The company's 2024 backlog in Biopharma Laboratory Services reached $7.90 billion, providing approximately $2.46 billion in near-term revenue visibility — a contracted pipeline that insulates the segment from short-term pharmaceutical R&D spending fluctuations. Labcorp signed or closed 13 health system and regional laboratory transactions in 2025, including partnerships with Baystate Health and Providence, converting competitors into customers and securing long-term volume commitments. That health system partnership strategy reflects a deliberate repositioning: rather than competing with hospital labs for testing volume, Labcorp is absorbing those labs into its network and providing the infrastructure that individual health systems cannot economically maintain independently.